Skip to main content
TipRanks
Go Ultimate75% OFF

GENOVA Inc. (9341) AI Stock Analysis

2 Followers
JP:9341

GENOVA Inc.

(TSE/TYO:9341)

Select Model
Rating:61Neutral
Price Target:JPY 591.00▲(3.14% Upside)
Action:reiterated
Date:08/17/26

The score is held back primarily by weakened 2026 fundamentals—sharp margin/ROE compression and a major deterioration in cash generation with negative free cash flow—despite strong revenue growth and modest leverage. Technicals are modestly supportive with price above key longer-term averages, and valuation is a relative strength given the solid dividend yield and reasonable P/E.

Positive Factors
Revenue GrowthSustained revenue expansion indicates that GENOVA continues to grow its business base and extend market reach. A multi-year top-line trend can support operating scale, reinforce customer adoption, and provide a foundation for rebuilding profitability if cost discipline improves over the coming quarters.
Negative Factors
Margin CompressionThe sharp margin reset reduces the quality and predictability of GENOVA’s earnings despite strong sales growth. If low-single-digit profitability persists, less revenue will convert into operating income, limiting reinvestment capacity and making future earnings more sensitive to cost changes.

GENOVA Inc. (9341) vs. iShares MSCI Japan ETF (EWJ)

-5%0%5%10%15%20%25%30%JP:9341+3.09%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 9.93B
Dividend Yield
5.24%
Average Volume (3M)
63.77K
Price to Earnings (P/E)
15.6
Beta (1Y)
0.67
Revenue Growth
46.39%
EPS Growth
12.53%
Country
Japan
Employees
529
Sector
General
Sector Strength
55
Industry
Software - Application

GENOVA Inc. Business Overview & Revenue Model

Company Description

Operating within Japan, GENOVA, Inc. focuses on the digital healthcare market, providing both medical platform services and smart clinic solutions. Its offerings include Medical Doc, a comprehensive online platform that distributes diverse content, s...

GENOVA Inc. Financial Statement Overview

Summary

Strong 2026 revenue growth (~24%) is a clear positive, and leverage remains modest. However, profitability deteriorated sharply with meaningful margin compression and a large decline in ROE, while cash conversion weakened significantly with very low operating cash flow relative to net income and negative free cash flow in 2026—pressuring overall financial quality.

Income Statement

58Neutral

Balance Sheet

76Positive

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue12.77B11.57B10.01B8.68B6.51B4.80B
Gross Profit6.76B6.47B7.38B6.55B4.79B3.50B
EBITDA513.44M543.85M2.11B2.38B1.79B1.09B
Net Income623.48M275.40M1.41B1.73B1.26B686.27M
Balance Sheet
Total Assets11.31B10.26B8.53B8.20B5.41B2.82B
Cash, Cash Equivalents and Short-Term Investments5.08B5.32B5.87B5.97B3.86B1.65B
Total Debt1.77B735.71M20.84M377.78M28.25M163.50M
Total Liabilities5.16B3.36B1.53B2.16B1.37B1.33B
Stockholders Equity6.15B6.90B7.00B6.04B4.04B1.49B
Cash Flow
Free Cash Flow0-46.98M1.06B1.77B1.11B513.36M
Operating Cash Flow053.85M1.19B1.82B1.20B623.77M
Investing Cash Flow0-809.75M-275.93M-94.24M-113.45M-179.06M
Financing Cash Flow0199.63M-1.01B376.82M1.13B59.88M

GENOVA Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price573.00

Price Trends

50DMA604.20Negative
100DMA609.71Negative
200DMA588.95Negative

Market Momentum

MACD-9.73Positive
RSI41.88Neutral
STOCH60.68Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9341, the sentiment is Negative. The current price of 573.00 is below the 20-day moving average (MA) of 588.05, below the 50-day MA of 604.20, and below the 200-day MA of 588.95, indicating a bearish trend. The MACD of -9.73 indicates Positive momentum. The RSI at 41.88 is Neutral, neither overbought nor oversold. The STOCH value of 60.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9341.

GENOVA Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:9341 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:9218JP:921868NeutralJPY 7.73B30.81―1.36%34.18%-32.29%
JP:9341JP:934161NeutralJPY 10.22B15.55―5.24%46.39%12.53%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4438JP:443854NeutralJPY 2.34B-4.31――14.84%30.67%
JP:4480JP:448054NeutralJPY 67.05B35.6711.30%―21.01%10.15%

* General Sector Average

Performance Comparison

-20%0%20%JP:9341JP:4480JP:4438JP:9218JP:366ADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:9341 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:9341GENOVA Inc.573.0010.501.87%
JP:4480Medley, Inc.2108.00-447.00-17.50%
JP:4438Welby Inc.274.00-57.00-17.22%
JP:9218Mental Health Technologies Co. Ltd.736.00-82.54-10.08%
JP:366AWellness Communications Corporation1100.00-135.96-11.00%

GENOVA Inc. Corporate Events

GENOVA Acquires “Karada ni Iikoto” Healthcare Media Business to Boost Medical Platform

Sep 11, 2026

GENOVA Inc. has agreed to acquire the “Karada ni Iikoto” healthcare media business from Central Medience Co., Ltd. for an expected 51 million yen in cash, obtaining contracted editorial services, sponsored content, and PR functions centered on the pl...

Genova Returns to Profit as Sales Surge and New Subsidiary Added

Aug 10, 2026

Genova Inc. reported a sharp 64.7% year-on-year increase in net sales to ¥3.06 billion for the quarter ended June 30, 2026, while operating and ordinary losses narrowed compared with the prior-year period, resulting in profit attributable to owners o...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026